Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE MALEATE AND GLIMEPIRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus ROSIGLITAZONE MALEATE AND GLIMEPIRIDE.
ACTOPLUS MET vs ROSIGLITAZONE MALEATE AND GLIMEPIRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Rosiglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in adipose tissue, skeletal muscle, and liver. Glimepiride is a sulfonylurea that stimulates insulin release from pancreatic beta cells by blocking ATP-sensitive potassium channels.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
Oral, initial dose 4 mg rosiglitazone/1 mg glimepiride once daily, titrate based on glycemic response; maximum dose 8 mg rosiglitazone/4 mg glimepiride once daily.
None Documented
None Documented
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Rosiglitazone: 3-4 hours. Glimepiride: 5-9 hours. Clinically, twice-daily dosing for rosiglitazone and once-daily for glimepiride.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Rosiglitazone: primarily hepatic metabolism with <1% excreted unchanged in urine; fecal (23%) and urinary (64%) elimination as metabolites. Glimepiride: ~60% excreted in urine as metabolites, ~40% in feces as metabolites.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione